Containing monoclonal antibodies
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; cell cultures, whether or not modified: > Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes: > Immunological products, put up in measured doses or in forms or packings for retail sale > Containing monoclonal antibodies
Duty Rate (from China)
Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Products classified under HTS 3002.15.00.11
Rituximab Monoclonal Antibody Injection
Rituximab is a genetically engineered chimeric monoclonal antibody targeting CD20 on B-cells, used for treating non-Hodgkin lymphoma and rheumatoid arthritis. It falls under HTS 3002.15.00.11 as an immunological product containing monoclonal antibodies, put up in measured doses for retail sale in pre-filled syringes or vials.
Trastuzumab (Herceptin) Infusion Vial
Trastuzumab is a humanized monoclonal antibody against HER2 protein, used in HER2-positive breast cancer therapy. Classified under HTS 3002.15.00.11 for its immunological role in targeted cancer treatment, supplied in measured dose vials for retail pharmacy sale.
Infliximab (Remicade) Lyophilized Powder
Infliximab is a chimeric monoclonal antibody against TNF-alpha for psoriasis and ulcerative colitis. HTS 3002.15.00.11 applies to this biotech-derived immunological product in measured retail doses for reconstitution.
Pembrolizumab (Keytruda) Injection
Pembrolizumab targets PD-1 for advanced cancer immunotherapy like Hodgkin lymphoma. HTS 3002.15.00.11 covers this monoclonal antibody immunological product in pre-filled syringes for retail therapeutic use.
Cetuximab (Erbitux) Infusion Kit
Cetuximab is a chimeric monoclonal antibody against EGFR for colorectal cancer. Under HTS 3002.15.00.11 for retail-measured doses regulating tumor immunology.
Denosumab (Prolia) Prefilled Syringe
Denosumab is a human monoclonal antibody inhibiting RANKL for osteoporosis. HTS 3002.15.00.11 applies to this immunological product in retail syringes.
Ranibizumab (Lucentis) Intravitreal Injection
Ranibizumab is a humanized monoclonal antibody fragment for wet AMD. Classified HTS 3002.15.00.11 as immunological VEGF inhibitor in measured doses.
Atezolizumab (Tecentriq) Concentrate
Atezolizumab is a humanized anti-PD-L1 monoclonal for bladder cancer. HTS 3002.15.00.11 for checkpoint immunological product.
Daratumumab (Darzalex) Injection
Daratumumab targets CD38 for multiple myeloma. HTS 3002.15.00.11 immunological monoclonal.
Blinatumomab (Blincyto) Kit
Blinatumomab is a bispecific T-cell engager monoclonal for ALL. HTS 3002.15.00.11.
Biosimilar Trastuzumab Injection
Biosimilar version of trastuzumab monoclonal antibody for HER2 cancers. HTS 3002.15.00.11 as interchangeable immunological product.
Adalimumab (Humira) Prefilled Syringe
Adalimumab is a fully human monoclonal antibody inhibiting TNF-alpha, for rheumatoid arthritis and Crohn's disease. It qualifies for HTS 3002.15.00.11 as a measured-dose immunological product for retail sale, regulating immune processes per chapter notes.
Bevacizumab (Avastin) IV Solution
Bevacizumab is a humanized monoclonal antibody blocking VEGF, used for colorectal and lung cancer. Under HTS 3002.15.00.11 for its role in immunological regulation via angiogenesis inhibition, in retail-measured vials.
Nivolumab (Opdivo) Concentrate for Infusion
Nivolumab is a human monoclonal antibody PD-1 inhibitor for melanoma and lung cancer immunotherapy. Classified in HTS 3002.15.00.11 as it directly regulates immunological processes via checkpoint inhibition, in measured retail vials.
Omalizumab (Xolair) Lyophilized Powder
Omalizumab is a humanized monoclonal antibody binding IgE for severe asthma treatment. It fits HTS 3002.15.00.11 as a biotech immunological product in measured doses for retail sale.